{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:48:18Z","timestamp":1753876098012,"version":"3.41.2"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a need to better understand ulcerative colitis (UC) patient and healthcare provider (HCP) treatment satisfaction, acceptability, and preferences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two international, cross-sectional, web-based surveys were conducted among participants of a phase 3 mirikizumab study (NCT03519945). The questions captured moderate-to-severe UC patients\u2019 experience, HCPs\u2019 perception of patients\u2019 experience, and HCPs\u2019 own experience with mirikizumab administration through intravenous (IV) infusions and subcutaneous (SC) injections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Respondents included 93 patients and 42 HCPs from 11 countries. The majority of patients had UC &amp;gt;4 years (74.2%), were bionaive (68%), in remission at the time of the survey (63%). HCPs were primarily from the United States (57%), generally nurses (41%) or gastroenterologists (26%) with \u22656 years of experience in treating UC (57%). Most patients were \u201cvery satisfied\/satisfied\u201d (IV, 83%; SC, 91%), \u201ccompletely\/somewhat\u201d accepting of mirikizumab administration (IV, 87%; SC, 97%), and agreed that improvement to their UC outweighed any administration dissatisfaction (90%). HCPs\u2019 perspectives of patients\u2019 experiences were higher: \u201cvery satisfied\/satisfied\u201d (IV, 93%; SC, 100%); \u201ccompletely\/somewhat\u201d accepting (IV, 90%; SC, 98%). HCPs themselves were \u201cvery satisfied\/satisfied\u201d (IV, 81%; SC, 95%); gastroenterologists were \u201cvery satisfied\u201d (IV, 82%; SC, 82%) more than nurses (IV, 29%; SC, 65%) who were generally at least \u201csatisfied\u201d (IV, 53%; SC, 35%). Two SC and monthly SC injections were \u201ccompletely acceptable\u201d by the patients (76% and 85%) and per HCPs\u2019 perceptions of patients\u2019 preferences (69% and 100%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Both patients and HCPs were satisfied with and accepted mirikizumab IV induction followed by monthly maintenance SC injections. UC improvement outweighed any administration dissatisfaction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otae054","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:12:54Z","timestamp":1728043974000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-8285","authenticated-orcid":false,"given":"David","family":"Clemow","sequence":"first","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-6680","authenticated-orcid":false,"given":"Christine","family":"Radawski","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-2253","authenticated-orcid":false,"given":"Joe","family":"Milata","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Alaka","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa Hunter","family":"Gibble","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Schaum","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obi","family":"Ezennia","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Martinez","sequence":"additional","affiliation":[{"name":"Gastroenterology Research of America , San Antonio, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"Szaloki","sequence":"additional","affiliation":[{"name":"Javorszky Hospital , Vac ,","place":["Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Ito","sequence":"additional","affiliation":[{"name":"NHO Mito Medical Center , Ibaraki ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-6999","authenticated-orcid":false,"given":"Danielle","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Evidera , Bethesda, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kirk","sequence":"additional","affiliation":[{"name":"Evidera , Bethesda, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"1","key":"2024102915181619500_CIT0001","first-page":"141","article-title":"Patients\u2019 perceive biologics to be riskier and more dreadful than other IBD medications","volume":"26","author":"Koliani-Pace","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2024102915181619500_CIT0002","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/biomedicines11082249","article-title":"Inflammatory bowel disease: emerging therapies and future treatment strategies","volume":"11","author":"Bretto","year":"2023","journal-title":"Biomedicines."},{"issue":"3","key":"2024102915181619500_CIT0003","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"37","key":"2024102915181619500_CIT0004","doi-asserted-by":"crossref","first-page":"e35020","DOI":"10.1097\/MD.0000000000035020","article-title":"Pathological mechanism and targeted drugs of ulcerative colitis: a review","volume":"102","author":"Guo","year":"2023","journal-title":"Medicine (Baltim)."},{"issue":"10","key":"2024102915181619500_CIT0005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA."},{"issue":"1","key":"2024102915181619500_CIT0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11938-017-0120-8","article-title":"Update on the use of biologic therapy in ulcerative colitis","volume":"15","author":"Aggarwal","year":"2017","journal-title":"Curr Treat Options Gastroenterol."},{"author":"NIDDK","key":"2024102915181619500_CIT0007"},{"volume-title":"CADTH rapid response reports: biologics versus immunomodulators for the treatment of ulcerative colitis: a review of comparative clinical effectiveness and cost-effectiveness","author":"Chao","key":"2024102915181619500_CIT0008"},{"issue":"1","key":"2024102915181619500_CIT0009","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"issue":"2","key":"2024102915181619500_CIT0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2036.2006.02974.x","article-title":"The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort","volume":"24","author":"Ho","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2024102915181619500_CIT0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40268-019-0263-2","article-title":"Ulcerative colitis: shifting sands","volume":"19","author":"D\u2019Haens","year":"2019","journal-title":"Drugs R D"},{"issue":"2","key":"2024102915181619500_CIT0012","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"2024102915181619500_CIT0013","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/1744666X.2022.2069562","article-title":"Emerging therapies for ulcerative colitis","volume":"18","author":"Hanzel","year":"2022","journal-title":"Expert Rev Clin Immunol."},{"key":"2024102915181619500_CIT0014","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.05.016","article-title":"Can IL-23 be a good target for ulcerative colitis","volume":"32-33","author":"Allocca","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol."},{"issue":"Supplement_2","key":"2024102915181619500_CIT0015","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2024102915181619500_CIT0016","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"2024102915181619500_CIT0017","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"2024102915181619500_CIT0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"2024102915181619500_CIT0019"},{"issue":"26","key":"2024102915181619500_CIT0020","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"2024102915181619500_CIT0021","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2024102915181619500_CIT0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-230X-12-108","article-title":"Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey","volume":"12","author":"Schreiber","year":"2012","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"2024102915181619500_CIT0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2024102915181619500_CIT0024","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","article-title":"Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease","volume":"28","author":"Irvine","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"8","key":"2024102915181619500_CIT0025","first-page":"1571","article-title":"The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol."},{"key":"2024102915181619500_CIT0026","doi-asserted-by":"crossref","first-page":"izad282","DOI":"10.1093\/ibd\/izad282","article-title":"Systematic literature review: ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators","author":"Dubinsky","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024102915181619500_CIT0027","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ajg.2017.470","article-title":"Optimizing selection of biologics in inflammatory bowel disease: development of an online patient decision aid using conjoint analysis","volume":"113","author":"Almario","year":"2018","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2024102915181619500_CIT0028","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.dld.2016.01.013","article-title":"Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study","volume":"48","author":"Peyrin-Biroulet","year":"2016","journal-title":"Dig Liver Dis."},{"issue":"7","key":"2024102915181619500_CIT0029","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/00365521.2022.2036808","article-title":"Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment","volume":"57","author":"Wickramasekera","year":"2022","journal-title":"Scand J Gastroenterol."},{"issue":"2","key":"2024102915181619500_CIT0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjac130","article-title":"Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]","volume":"17","author":"Louis","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2024102915181619500_CIT0031","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s12325-022-02143-z","article-title":"Inflammatory bowel disease patients\u2019 treatment preferences using a discrete choice experiment technique: the InPuT study","volume":"39","author":"Schubert","year":"2022","journal-title":"Adv Ther."},{"key":"2024102915181619500_CIT0032","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae015","article-title":"Patient preferences for treatment attributes in inflammatory bowel disease: results from a large survey across seven european countries using a discrete choice experiment","author":"Fiorino","year":"2024","journal-title":"Inflamm Bowel Dis."},{"issue":"9","key":"2024102915181619500_CIT0033","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","article-title":"Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration","volume":"15","author":"Denesh","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"7","key":"2024102915181619500_CIT0034","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4321\/S1130-01082013000700003","article-title":"Inflammatory bowel disease patient\u2019s satisfaction with healthcare services received. Physicians\u2019 and nurses\u2019 perceptions","volume":"105","author":"Casellas","year":"2013","journal-title":"Rev Esp Enferm Dig."},{"issue":"2","key":"2024102915181619500_CIT0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jgh3.12235","article-title":"Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: a systematic review","volume":"4","author":"Prasad","year":"2020","journal-title":"JGH Open"},{"issue":"41","key":"2024102915181619500_CIT0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/RHXR5192","article-title":"Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study","volume":"26","author":"Coates","year":"2022","journal-title":"Health Technol Assess."},{"issue":"2","key":"2024102915181619500_CIT0037","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology."},{"issue":"6","key":"2024102915181619500_CIT0038","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol."},{"issue":"6","key":"2024102915181619500_CIT0039","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/ibd\/izae096","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae054\/59593762\/otae054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae054\/60197312\/otae054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae054\/60197312\/otae054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T15:18:39Z","timestamp":1730215119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae054\/7810928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae054","relation":{},"ISSN":["2631-827X"],"issn-type":[{"type":"electronic","value":"2631-827X"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"otae054"}}